Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Company News
Events
Directory
Search
Close search
Home
Company
Xellia Pharmaceuticals
Xellia Pharmaceuticals
X
LinkedIn
Trending Articles
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
CordenPharma & GENEPEP collaborate to leverage peptide drug substance discovery
The partnership has facilitated the expedition of the development, discovery and manufacturing of peptides for early clinical phase
ISPE announces 2024 Facility of the Year Awards category winners
The awards programme recognises pharmaceutical companies that are the 'best' in the industry for innovation, operations, digitalisation, supply chain and social impact
Tabletability, compactability and compressibility: What’s the difference?
To patients and consumers, tablets are a simple and convenient dosage form, but the science behind compressing a block of particles or granules into a single tablet can be...
Chemistry, manufacturing and control (CMC) as key drivers for drug discovery success
Embracing collaborative strategies not only accelerates drug development programmes but also fosters science-based milestone decisions, mitigates risks and prepares for...
Upcoming event
Making Pharmaceuticals
23–24 April 2024 | Exhibition | Coventry, UK
See all
Related Content
Manufacturing
Xellia Cleveland manufacturing facility operational for anti-infectives
In addition to commencing commercial supply, the facility is also preparing ramp-up of its recently installed aseptic bag manufacturing line
Ingredients
Xellia Pharmaceuticals launches additional Vanco Ready doses
Vanco Ready will now cover relevant doses from 500 mg to 2 g in 250 mg increments
Regulatory
Xellia Pharmaceuticals expands approved doses of VANCO READYTM
The drug is universally recognised as a key intervention in the management of sepsi at life-threatening state, as well as other infections
Recruitment
Career Opportunities: Automation Engineer (7243)
Xellia Pharmaceuticals is owned by Novo Holding A/S and is a specialty pharmaceutical company leading in the development, manufacture and supply of anti-infective treatments
Recruitment
Career Opportunities: Global Packaging Manager, Sterile Products (5677)
Xellia Pharmaceuticals is owned by Novo Holding A/S and is a specialty pharmaceutical company leading in the development, manufacture and supply of anti-infective treatments
Recruitment
Career Opportunities: Senior Logistics and Process Engineer (6982)
Xellia Pharmaceuticals is owned by Novo Holding A/S and is a specialty pharmaceutical company leading in the development, manufacture and supply of anti-infective treatments
Recruitment
Career Opportunities: Sr Scientist, On Market Products (5942)
Xellia Pharmaceuticals is owned by Novo Holding A/S and is a specialty pharmaceutical company leading in the development, manufacture and supply of anti-infective treatments
Subscribe now